Nasdaq:US$18.44 (-0.77) | HKEX:HK$29.35 (-1.20) | AIM:£2.73 (-0.13)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases in patients with advanced solid tumors